PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Jake S. O’Donnell(The University of Queensland), Mario Mandalà(University of Perugia), Michele W.L. Teng(The University of Queensland), Daniela Massi(University of Florence)
Cited by 366
Related Papers
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k